NEIMETH Stock Overview
Manufactures and markets pharmaceutical and animal health care products in Nigeria and Ghana. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Neimeth International Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₦2.00 |
| 52 Week High | ₦2.39 |
| 52 Week Low | ₦1.51 |
| Beta | 0.34 |
| 1 Month Change | 2.04% |
| 3 Month Change | -0.50% |
| 1 Year Change | 5.26% |
| 3 Year Change | 14.29% |
| 5 Year Change | 250.88% |
| Change since IPO | -2.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEIMETH | NG Pharmaceuticals | NG Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 2.5% |
| 1Y | 5.3% | -7.3% | 51.2% |
Return vs Industry: NEIMETH exceeded the NG Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: NEIMETH underperformed the NG Market which returned 51.2% over the past year.
Price Volatility
| NEIMETH volatility | |
|---|---|
| NEIMETH Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in NG Market | 8.5% |
| 10% least volatile stocks in NG Market | 3.1% |
Stable Share Price: NEIMETH has not had significant price volatility in the past 3 months compared to the NG market.
Volatility Over Time: NEIMETH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 202 | J. Valentine Okelu | www.neimethplc.com.ng |
Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical and animal health care products in Nigeria and Ghana. The company operates through two segments, Pharmaceuticals and Animal Health. It also provides health care, ethical, and veterinary related products; and poultry and a range of anthelmintic products, as well as enhancing medicaments.
Neimeth International Pharmaceuticals Plc Fundamentals Summary
| NEIMETH fundamental statistics | |
|---|---|
| Market cap | ₦8.55b |
| Earnings (TTM) | -₦1.98b |
| Revenue (TTM) | ₦3.79b |
2.3x
P/S Ratio-4.3x
P/E RatioIs NEIMETH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEIMETH income statement (TTM) | |
|---|---|
| Revenue | ₦3.79b |
| Cost of Revenue | ₦2.22b |
| Gross Profit | ₦1.58b |
| Other Expenses | ₦3.56b |
| Earnings | -₦1.98b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 41.58% |
| Net Profit Margin | -52.28% |
| Debt/Equity Ratio | 231.6% |
How did NEIMETH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neimeth International Pharmaceuticals Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Meristem Securities Limited |